Novo Nordisk Taps Start-Up for New Oral Weight-Loss Drugs

Novo Nordisk has partnered with Vivtex Corporation to license oral drug-delivery technologies for weight loss and diabetes, agreeing to pay up to $2.1 billion in milestone payments.